Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03510208 · ClinicalTrials.gov registry record · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
A Phase 1 study of Malignant Glioma and Malignant Brain Neoplasm, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT03510208 is a Phase 1 study of Malignant Glioma and Malignant Brain Neoplasm that is actively recruiting participants, run by Stanford University. The registered enrollment target is 46 participants, below the 91-participant average among 40 other Malignant Glioma trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03510208, a Phase 1 study of Malignant Glioma and Malignant Brain Neoplasm, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better distinguish tumor cells from normal brain tissue and identify small tumors that cannot be seen using current imaging methods.
Conditions Studied
Interventions
- BIOLOGICAL Panitumumab
- DRUG Panitumumab-IRDye800
- PROCEDURE Near-Infrared Fluorescence Imaging
- DEVICE POINPOINT-IR9000
Study Locations (1)
California
- Stanford University School of Medicine - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2018-05-16 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03510208
The ClinicalTrials.gov registry entry for NCT03510208 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 40 other Malignant Glioma trials with a reported enrollment target (49% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Malignant Glioma appearing as the primary indexed condition, and to 4 interventions - of which Panitumumab is the first listed.
NCT03510208 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03510208 about?
NCT03510208 is a clinical study titled "Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery". The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better di...
What is the current status of trial NCT03510208?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2018-05-16. Estimated completion is 2026-05.
What conditions does trial NCT03510208 study?
This clinical trial studies the following conditions: Malignant Glioma, Malignant Brain Neoplasm.
What interventions are being tested in trial NCT03510208?
The interventions under investigation include: Panitumumab (BIOLOGICAL), Panitumumab-IRDye800 (DRUG), Near-Infrared Fluorescence Imaging (PROCEDURE), POINPOINT-IR9000 (DEVICE).
Who is sponsoring clinical trial NCT03510208?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03510208 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
RECRUITING · Phase 1
-
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
RECRUITING · Phase 1
-
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
RECRUITING · Phase 1
-
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
ACTIVE NOT RECRUITING · Phase 1
-
PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.